Evidence map›Paper›PMID 34178137›Full record

ReviewExperimental and therapeutic medicine2021

Renal replacement therapy in cancer patients with acute kidney injury (Review).

Mircea Lupuşoru, Gabriela Lupuşoru, Ioana Ailincăi, Georgiana Frățilă, Andreea Andronesi, Elena Micu, Mihaela Banu, Radu Costea, Gener Ismail

Open access · diamondAbstract readReview
In one paragraph

Review in Experimental and therapeutic medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Mircea LupuşoruDepartment of Physiology 1, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Gabriela LupuşoruDepartment of Nephrology, 'Fundeni' Clinical Institute, 022328 Bucharest, Romania.
Ioana AilincăiDepartment of Nephrology, 'Fundeni' Clinical Institute, 022328 Bucharest, Romania.
Georgiana FrățilăDepartment of Nephrology, 'Fundeni' Clinical Institute, 022328 Bucharest, Romania.
Andreea AndronesiDepartment of Nephrology, 'Fundeni' Clinical Institute, 022328 Bucharest, Romania.
Elena MicuDepartment of Nephrology, 'Fundeni' Clinical Institute, 022328 Bucharest, Romania.
Mihaela BanuDepartment of Morphology, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Radu CosteaDepartment of General Surgery, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Gener IsmailDepartment of Physiology 1, 'Carol Davila' University of Medicine and Pharmacy, 020021 Bucharest, Romania.
Institutul Clinic Fundeni · ROCarol Davila University of Medicine and Pharmacy · RO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cancer patients are at high risk for developing acute kidney injury (AKI), which is associated with increased morbidity and mortality in these patients. Despite the progress made in understanding the pathogenic mechanisms and etiology of AKI in these patients, the main prevention consists of avoiding medication and nephrotoxic agents such as non-steroidal anti-inflammatory drugs, contrast agents used in medical imaging and modulation of chemotherapy regimens; when prophylactic measures are overcome and renal impairment becomes unresponsive to treatment, renal replacement therapy (RRT) is required. There are several methods of RRT that can be utilized for patients with malignancies and acute renal impairment; the choice of treatment being based on the patient characteristics. The aim of this article is to review the literature data regarding the epidemiology and management of AKI in cancer patients, the extracorporeal techniques used, choice of the appropriate therapy and the optimal time of initiation, and also the dose-prognosis relationship.

Indexed as

acute kidney injurycancercontinuous renal replacement therapyhybrid therapyintermittent renal replacement therapy

Identifiers

PMID34178137
PMCPMC8220659
OpenAlexW3172906487

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.